Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals develops RNA-targeted therapeutics for various indications. They offer existing treatments for spinal muscular atrophy (SMA), hereditary transthyretin amyloidosis, and familial chylomicronemia syndrome. The company also has multiple medicines in phase 3 studies, including treatments for ATTR, hereditary angioedema, amyotrophic lateral sclerosis, cardiovascular disease, and hepatitis B virus.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |